Yes, Trulicity is a GLP-1 receptor agonist. Its active ingredient, dulaglutide, is a lab-made version of a hormone your body naturally produces called GLP-1 (glucagon-like peptide-1). Trulicity is FDA-approved for adults and children 10 and older with type 2 diabetes, and it also has a separate approval for reducing cardiovascular risk in adults with type 2 diabetes who have heart disease or multiple risk factors.
How Trulicity Works as a GLP-1
Your gut naturally releases GLP-1 after you eat. This hormone does several things at once: it signals your pancreas to release more insulin, tells your liver to produce less sugar, slows down how quickly food leaves your stomach, and helps you feel full sooner. The problem is that natural GLP-1 breaks down in your body within minutes.
Dulaglutide is engineered to last much longer. It mimics all of those natural effects but sticks around in your system for about a week, which is why Trulicity is a once-weekly injection rather than something you take daily. By keeping insulin levels responsive to meals and dialing back the liver’s sugar output, it helps bring down blood sugar levels over time. The slower stomach emptying also contributes to reduced appetite, though Trulicity is not specifically approved as a weight loss medication.
How Trulicity Compares to Other GLP-1 Drugs
Trulicity belongs to the same drug class as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), but there are practical differences. Trulicity comes in a pre-filled, single-use pen that doesn’t require you to handle a needle or mix anything. You inject it once a week in your stomach, thigh, or upper arm.
One distinction worth noting is cardiovascular data. In the REWIND trial, which enrolled nearly 10,000 patients, Trulicity at 1.5 mg reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 12% compared to placebo. The event rate dropped from 13.4% in the placebo group to 12.0% in the Trulicity group. This is why the FDA granted it a specific cardiovascular indication, something not all GLP-1 drugs carry for the same patient populations.
Common Side Effects
Because GLP-1 drugs slow digestion and change how your gut processes food, the most common side effects are gastrointestinal. With Trulicity, people frequently report nausea, diarrhea, vomiting, stomach pain, and reduced appetite. These symptoms tend to be worst when you first start the medication or when your dose increases, and they often improve over the first few weeks as your body adjusts.
Less bothersome but still common are bloating, gas, heartburn, belching, and a general feeling of fullness. For most people these are mild enough to manage, but severe or persistent nausea and vomiting warrant a conversation with your prescriber about adjusting the dose or timing.
Thyroid Cancer Warning
Trulicity carries a boxed warning, the most serious type the FDA issues, about thyroid tumors. In animal studies, dulaglutide caused thyroid C-cell tumors in rats at higher doses and with longer exposure. Whether this translates to humans is unknown, but the FDA requires the warning as a precaution.
Because of this risk, Trulicity is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you notice a lump in your neck, difficulty swallowing, or persistent hoarseness while taking Trulicity, those are symptoms worth bringing up promptly.
Who Trulicity Is Approved For
Trulicity has two distinct FDA-approved uses. The first is improving blood sugar control in adults and pediatric patients 10 years and older with type 2 diabetes, alongside diet and exercise. The second is reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who already have established cardiovascular disease or multiple cardiovascular risk factors.
Trulicity is not approved for type 1 diabetes, and it is not currently approved as a standalone weight loss drug, even though weight reduction is a common effect of GLP-1 medications. Other members of the GLP-1 class, particularly semaglutide under the brand name Wegovy, have separate approvals specifically for weight management.